

Figure 3

How genomic profiling fits into the flow of information in the perioperative interval




Figure 4 Allele Panel

Gene	Polymorphism	Incidence	Complication	Contra-indicated	Indicated
BChE	A209G	0.05%/4% * ("attraction")		intervention	Intervention
	G1615A	allele")	prolonged apnea	succinylcholine,	use intermediate
		1.3%/20% * /"K_	with succinylcholine	mivacurium	duration non-
		variant")			depolarizing muscle
CYP2D6	G1934A	** %99	inachaniata	- 1 - 1 - 2 - 1	relaxants
	deletion	17%**	analdesia with	omit codeine	use NSAIDs, other
	A263 deletion	4%**	Codeine.		opioids; monitor
	T1795 deletion	4%**	antiarryhthmic: and		plasma levels for
			frievelie		drug toxicity; adjust
			antidepressant		dose, take drug interaction
MTHFR	C677T	130/ /2000/ *	toxicity		precautions
	A1298C	12%/>30%	elevated blood	nitrous oxide	avoid nitrous oxide:
		new, flot known with	homocysteine		take thrombosis
MS (MTR)	A2756G	2%/35%*	levels; thrombosis		precautions
MTRR	A66G	29%****			
CBS	Intron 7 68bp	1%/12%*			
3.1	- 1				
١٧٠	G1691A	****	hyper-coagulable	If known in	take thrombosis
Drothrombin			state	advance avoid	and unforced
	G20210A	2%****		prolonged	919020
RYR1	G6502A	70/ ***		ımmobilization.	
	G1021A	6-10% ***	dysrhythmia,	succinylcholine;	use nitrous oxide
		4%***	rigidity, renai	volatile anesthetic	and non-depolarizing
		4%***	lallure, DIC	agents	muscle relaxants
		4%***	infravacular		
		4%***	Coogniption) donth		
CACNA18	G3257A	4 families	coaguiation), death		
αN	G-308A	16%****	exaggerated	No specific contra-	failor immino
TNF-B	G+252A			indication	modulation; detect
-		~**** &£% ****	lesponse		inflammatory
					complications early;
					water for infection

homozygote/heterozygote of poor metabolizers of manifesting phenotypes allele frequency * * * *

Comparison of INVADER Assay with PCR-RFLP for Detection of Allelic Variants Figure 5

Assay	Gene	Format	Discrepant	Total
Drug Metabolism				
BCHE G1615A, K variant	butyrlcholinesterase	Monoplex	0	145
BCHE A209G, Atypical	· ·	Monoplex	0	164
CYP2D6*3	cytochrome P450 2D6	Biplex	, O	168
CYP2D6*4) on deal	Biplex	ო	164
CYP2D6*5		Biplex	not done	176
CYP2D6*6	. (916	Biplex	0	163
Thrombosis	0.4			
FVL G1691A	Factor V	Monoplex	_	132
Prothrombin FII G20210A	Factor II	Monoplex	, O	140
Homocycteine Level	von.			
MTHFR C677T	methylenetrahydrofolate reductase Monoplex	Monoplex	0	145
MTHFR A1298C		Monoplex	0	150
CBS ins68	cystathione beta synthase	Monoplex	0	158
MTR (MS) A2756G	methionine synthase	Monoplex	0	147
MTRR A66G	methioninie synthase reductase	Monoplex	7	150
Inflammation				
TNFalpha -308	tumor necrosis factor alpha	Monoplex	2	163
TNFbeta +252	tumor necrosis factor beta	Monoplex	0	163
Total (excluding 2D6*5)	ecang In		8	2152
Concordance (unresolved)				99.63%